[HTML][HTML] Vascular tissue engineering: progress, challenges, and clinical promise

HHG Song, RT Rumma, CK Ozaki, ER Edelman… - Cell stem cell, 2018 - cell.com
Although the clinical demand for bioengineered blood vessels continues to rise, current
options for vascular conduits remain limited. The synergistic combination of emerging …

[HTML][HTML] Guía clínica española del acceso vascular para hemodiálisis

J Ibeas, R Roca-Tey, J Vallespín, T Moreno, G Moñux… - Nefrología, 2017 - Elsevier
Vascular access for haemodialysis is key in renal patients both due to its associated
morbidity and mortality and due to its impact on quality of life. The process, from the creation …

KDOQI clinical practice guideline for vascular access: 2019 update

CE Lok, TS Huber, T Lee, S Shenoy, AS Yevzlin… - American Journal of …, 2020 - Elsevier
Abstract The National Kidney Foundation's Kidney Disease Outcomes Quality Initiative
(KDOQI) has provided evidence-based guidelines for hemodialysis vascular access since …

[HTML][HTML] Editor's choice–vascular access: 2018 clinical practice guidelines of the European Society for Vascular Surgery (ESVS)

J Schmidli, MK Widmer, C Basile, G de Donato… - European Journal of …, 2018 - ejves.com
CHF Congestive heart failure CKD Chronic kidney disease CO Cardiac output CO2 Carbon
dioxide CPR Cardiopulmonary recirculation CTA Computed tomography angiography CVD …

Bioengineered human acellular vessels for dialysis access in patients with end-stage renal disease: two phase 2 single-arm trials

JH Lawson, MH Glickman, M Ilzecki, T Jakimowicz… - The Lancet, 2016 - thelancet.com
Background For patients with end-stage renal disease who are not candidates for fistula,
dialysis access grafts are the best option for chronic haemodialysis. However …

[HTML][HTML] The Lutonix AV randomized trial of paclitaxel-coated balloons in arteriovenous fistula stenosis: 2-year results and subgroup analysis

SO Trerotola, TF Saad, P Roy-Chaudhury… - Journal of Vascular and …, 2020 - Elsevier
Purpose To present final, 2-year results of a randomized trial comparing paclitaxel-coated vs
uncoated balloon angioplasty following vessel preparation with ultra–high-pressure …

[HTML][HTML] Chronic mesenteric ischemia: clinical practice guidelines from the Society for Vascular Surgery

TS Huber, M Björck, A Chandra, WD Clouse… - Journal of vascular …, 2021 - Elsevier
Background Chronic mesenteric ischemia (CMI) results from the inability to achieve
adequate postprandial intestinal blood flow, usually from atherosclerotic occlusive disease …

Vascular access in haemodialysis: strengthening the Achilles' heel

MC Riella, P Roy-Chaudhury - Nature Reviews Nephrology, 2013 - nature.com
Despite all the progress achieved since Scribner first introduced the arteriovenous (AV)
shunt in 1960 and Cimino and Brescia introduced the native AV fistula in 1962, we have …

Paclitaxel-coated balloon angioplasty vs. plain balloon dilation for the treatment of failing dialysis access: 6-month interim results from a prospective randomized …

K Katsanos, D Karnabatidis, P Kitrou… - Journal of …, 2012 - journals.sagepub.com
Purpose To report the 6-month results of a prospective randomized trial investigating
angioplasty with paclitaxel-coated balloons (PCB) vs. plain balloon angioplasty (BA) for the …

Definitions and end points for interventional studies for arteriovenous dialysis access

GA Beathard, CE Lok, MH Glickman… - Clinical Journal of the …, 2018 - journals.lww.com
This paper is part of the Clinical Trial Endpoints for Dialysis Vascular Access Project of the
American Society of Nephrology Kidney Health Initiative. The purpose of this project is to …